Abstract No. 27 Proton pump inhibitor use is associated with increased risk of post–transjugular intrahepatic portosystemic shunt hepatic encephalopathy: replication in an independent patient cohort

Abstract

Hepatic encephalopathy (HE) is a common complication of transjugular intrahepatic portosystemic shunt (TIPS) procedures. Proton pump inhibitor (PPI) use has recently been implicated as a risk factor for HE, potentially due to alterations in the gastrointestinal tract microbiome or effects on ammonium ion excretion. Although generally supporting an association between PPI use and HE, multiple meta-analyses have reported heterogeneity and publication bias, and only two previous studies have examined the role of PPI use in post-TIPS HE.